Clinical trial
Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute…
NCT00284986 · Mesoblast, Inc., Industry · Completed
Key facts
| NCT number | NCT00284986 |
|---|---|
| Title | Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants |
| Official title | A Phase II Open Label Study to Evaluate the Safety and Efficacy of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Salvage of Treatment-Refractory Acute GVHD Patients |
| Lead sponsor | Mesoblast, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease |
| Intervention type | Drug |
| Interventions | Prochymal |
| Enrollment | 11 |
| Start date | Nov 18, 2005 |
| Primary completion | Apr 25, 2006 |
| Completion | Feb 8, 2007 |
| First posted | Feb 1, 2006 |
| Last update posted | Oct 30, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: